目次

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING PREVALENCE OF DIABETIC NEUROPATHY
4.2.2 INCREASING HEALTHCARE EXPENDITURE
4.2.3 GROWING NUMBER OF INCIDENCE OF TRAUMA FROM INJURY AND OTHER CONDITIONS
4.3 RESTRAINTS
4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE THERAPEUTIC TREATMENT
4.3.2 LACK OF AWARENESS ABOUT THE NEUROLOGICAL CONDITION
4.4 OPPORTUNITIES
4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT ANALYSIS OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON ONGOING TREATMENTS AND DELAYED AVAILABILITY DUE TO DEFERMENT
5.3.3 IMPACT ON NUMBER OF PATIENTS

6 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE
6.1 OVERVIEW
6.2 PERIPHERAL NEUROPATHY
6.3 ENTRAPMENT NEUROPATHY
6.4 TRIGEMINAL NEURALGIA
6.5 PHANTOM LIMB PAIN
6.6 POST HERPETIC NEURALGIA (PHN)
6.7 POST TRAUMATIC NEUROPATHY

7 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION
7.1 OVERVIEW
7.2 DIABETIC NEUROPATHY
7.3 SPINAL STENOSIS
7.4 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY
7.5 OTHERS

8 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS
8.1 OVERVIEW
8.2 IMAGING
8.3 BLOOD TESTS
8.4 PHYSICAL EXAMINATION

9 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT
9.1 OVERVIEW
9.2 MEDICATION
9.3 MULTIMODAL THERAPY

10 GLOBAL NEUROPATHIC PAIN SMARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 RETAIL PHARMACIES & DRUG STORES
10.3 ONLINE PHARMACIES

11 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 RESEARCH ORGANIZATIONS

12 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION
12.1 OVERVIEW
12.2 AMERICAS
12.2.1 NORTH AMERICA
12.2.1.1 US
12.2.1.2 CANADA
12.2.2 LATIN AMERICA
12.3 EUROPE
12.3.1 WESTERN EUROPE
12.3.1.1 GERMANY
12.3.1.2 UK
12.3.1.3 FRANCE
12.3.1.4 ITALY
12.3.1.5 SPAIN
12.3.1.6 REST OF WESTERN EUROPE
12.3.2 EASTERN EUROPE
12.4 ASIA-PACIFIC
12.4.1 CHINA
12.4.2 INDIA
12.4.3 JAPAN
12.4.4 SOUTH KOREA
12.4.5 AUSTRALIA
12.4.6 REST OF ASIA-PACIFIC
12.5 MIDDLE EAST & AFRICA
12.5.1 MIDDLE EAST
12.5.2 AFRICA

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 COMPETITIVE BENCHMARKING
13.3 GLOBAL NEUROPATHIC PAIN MARKET: COMPANY RANKING, 2020
13.4 MAJOR GROWTH STRATEGY IN THE GLOBAL NEUROPATHIC PAIN MARKET
13.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS
13.6 COMPETITIVE BENCHMARKING: GLOBAL NEUROPATHIC PAIN MARKET
13.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
13.7.1 PRODUCT APPROVALS AND LAUNCHES
13.7.2 ACQUISITIONS
13.8 FINANCIAL MATRIX

14 COMPANY PROFILES
14.1 ABBOTT
14.1.1 COMPANY OVERVIEW
14.1.2 FINANCIAL OVERVIEW
14.1.3 PRODUCTS/SERVICES OFFERED
14.1.4 KEY DEVELOPMENTS
14.1.5 SWOT ANALYSIS
14.1.6 KEY STRATEGIES
14.2 PFIZER
14.2.1 COMPANY OVERVIEW
14.2.2 FINANCIAL OVERVIEW
14.2.3 PRODUCTS/SERVICES OFFERED
14.2.4 KEY DEVELOPMENTS
14.2.5 SWOT ANALYSIS
14.2.6 KEY STRATEGIES
14.3 JOHNSON & JOHNSON SERVICES, INC.
14.3.1 COMPANY OVERVIEW
14.3.2 FINANCIAL OVERVIEW
14.3.3 PRODUCTS/SERVICES OFFERED
14.3.4 KEY DEVELOPMENTS
14.3.5 SWOT ANALYSIS
14.3.6 KEY STRATEGIES
14.4 BAXTER INTERNATIONAL
14.4.1 COMPANY OVERVIEW
14.4.2 FINANCIAL OVERVIEW
14.4.3 PRODUCTS/SERVICES OFFERED
14.4.4 KEY DEVELOPMENTS
14.4.5 SWOT ANALYSIS
14.4.6 KEY STRATEGIES
14.5 ELI LILY AND COMPANY
14.5.1 COMPANY OVERVIEW
14.5.2 FINANCIAL OVERVIEW
14.5.3 PRODUCTS/SERVICES OFFERED
14.5.4 KEY DEVELOPMENTS
14.5.5 SWOT ANALYSIS
14.5.6 KEY STRATEGIES
14.6 GLAXOSMITHKLINE PLC
14.6.1 COMPANY OVERVIEW
14.6.2 FINANCIAL OVERVIEW
14.6.3 PRODUCTS/SERVICES OFFERED
14.6.4 KEY DEVELOPMENTS
14.6.5 SWOT ANALYSIS
14.6.6 KEY STRATEGIES
14.7 SANOFI
14.7.1 COMPANY OVERVIEW
14.7.2 FINANCIAL OVERVIEW
14.7.3 PRODUCTS/SERVICES OFFERED
14.7.4 KEY DEVELOPMENTS
14.7.5 SWOT ANALYSIS
14.7.6 KEY STRATEGIES
14.8 ASTRAZENECA
14.8.1 COMPANY OVERVIEW
14.8.2 FINANCIAL OVERVIEW
14.8.3 PRODUCTS/SERVICES OFFERED
14.8.4 KEY DEVELOPMENTS
14.8.5 SWOT ANALYSIS
14.8.6 KEY STRATEGIES
14.9 DEPOMED INC. (ASSERTIO THERAPEUTICS, INC)
14.9.1 COMPANY OVERVIEW
14.9.2 FINANCIAL OVERVIEW
14.9.3 PRODUCTS/SERVICES OFFERED
14.9.4 KEY DEVELOPMENTS
14.9.5 SWOT ANALYSIS
14.9.6 KEY STRATEGIES
14.10 BIOGEN, INC.
14.10.1 COMPANY OVERVIEW
14.10.2 FINANCIAL OVERVIEW
14.10.3 PRODUCTS/SERVICES OFFERED
14.10.4 KEY DEVELOPMENTS
14.10.5 SWOT ANALYSIS
14.10.6 KEY STRATEGIES
14.11 ASTELLAS PHARMA LTD.
14.11.1 COMPANY OVERVIEW
14.11.2 FINANCIAL OVERVIEW
14.11.3 PRODUCTS/SERVICES OFFERED
14.11.4 KEY DEVELOPMENTS
14.11.5 SWOT ANALYSIS
14.11.6 KEY STRATEGIES

15 APPENDIX
15.1 REFERENCES
15.2 RELATED REPORTS